Phase 3 N=55 Trial of D-Cycloserine in Schizophrenia
Schizophrenia
Primary: Scale for the Assessment of Negative Symptoms (SANS) — -.46; -.41 units on a scale/weeks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=200 Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
Anemia · Traumatic Brain Injury
Primary: Glasgow Outcome Scale — 17; 17; 34; 37 participants — p=.01
Phase 3 N=192 Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) at Week 12 — 24.62; 25.12; -10.03; -9.18 mmHg
Phase 3 N=22 Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Measurement of Apolipoprotein B48 and Apolipoprotein B100 Production Rates With Stable Isotope During Postprandial Period — 2.1; 2.5; 27.5; 30.3 mg/kg/day
Phase 3 N=24 Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults
Alpha 1-Antitrypsin Deficiency
Primary: Alpha-1 MP vs. Prolastin® of Area Under the Curve (AUC) From Day 0 to Day 7 — 155.9; 152.4 mg*h/mL
Phase 3 N=123 A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Parkinson's Disease Psychosis
Primary: Antipsychotic Efficacy — -4.4; NA; -6.5; NA Scores on the SAPS H+D scale
Phase 3 N=374 Evaluation of Prucalopride in Male Subjects With Chronic Constipation.
Male Subjects With Chronic Constipation
Primary: The Percentage of Subjects With an Average of ≥3 Spontaneous Complete Bowel Movements (SCBM) Per Week — 17.7; 37.9 percentage of subjects — p=<0.0001
Phase 3 N=26 Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH
Nonalcoholic Steatohepatitis · Liver Diseases
Primary: The Number of Participants With a 30% Reduction in Alanine Aminotransferase (ALT) Treated With Pentoxifylline (PTX) or Placebo for 12 Months. — 19; 7 participants — p=0.46
Phase 3 N=566 Low-Literacy Physician-Patient Intervention Promoting Colorectal Cancer Screening
Colorectal Cancer
Primary: Colorectal Cancer (CRC) Screening Completion — 17; 69 participants — p=0.32
Phase 3 N=406 Intravitreal Aflibercept Injection in Vision Impairment Due to DME
Diabetes Mellitus · Macular Edema
Primary: Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation…
Phase 3 N=330 Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
Thyroid Cancer
Primary: Progression-Free Survival (PFS) — 11.2; 4.0 months
Phase 3 N=179 Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia
Smoking Cessation · Schizophrenia
Primary: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Cognition Domains — 96; 95 units on a scale — p=<0.05
Phase 3 N=666 TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Skin and Subcutaneous Tissue Bacterial Infections
Primary: The Early Clinical Response Rate — 283; 276 participants
Phase 3 N=48 The Nasal Changes Affected by Different Alar Base Suture Techniques After Maxillary LeFort I Osteotomy
Conditions in T74.31 or T76.31
Primary: Soft and Hard Tissue Landmarks Movement — 0.95; -0.5; -0.95; -0.32 mm — p=0.098
Phase 3 N=60 Dronabinol Naltrexone Treatment for Opioid Dependence
Opioid Dependence
Primary: Opiate Withdrawal Measured by the Subjective Opiate Withdrawal Scale (SOWS) . — 11.16; 13.36 units on a scale